CytomX Therapeutics, Inc.

CTMX

US23284F1057

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-28 EDT			5-day change	1st Jan Change
1.22 ^USD	-3.17%		-5.43%	-21.29%

06-17	CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer	CI
05-28	Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	MT

CytomX Therapeutics, Inc. Announces Retirement of Frederick W. Gluck from Board of Directors

March 23, 2022 at 04:15 pm

CytomX Therapeutics, Inc. announced that Frederick W. Gluck is retiring from its board of directors, effective June 30, 2022.

Latest news about CytomX Therapeutics, Inc.

CytomX Therapeutics, Inc. Promotes Chris Ogden to Chief Financial Officer	06-17	CI
Piper Sandler Upgrades CytomX Therapeutics to Overweight From Neutral, Adjusts Price Target to $3.50 From $2.25	05-28	MT
BMO Capital Adjusts Price Target on CytomX Therapeutics to $3.59 From $3.25, Maintains Market Perform Rating	05-09	MT
Wedbush Upgrades CytomX Therapeutics to Outperform From Neutral, Adjusts Price Target to $8 From $3	05-09	MT
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q1 Revenue $41.5M	05-08	MT
Transcript : CytomX Therapeutics, Inc., Q1 2024 Earnings Call, May 08, 2024	05-08
CytomX Therapeutics Announces Positive Initial Phase 1a Dose Escalation Data for Monotherapy CX-904 (EGFRxCD3 PROBODY® T-Cell Engager)	05-08	CI
CytomX Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-08	CI
CytomX Therapeutics, Inc. Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with Keytruda® (pembrolizumab)	05-07	CI
Jefferies Upgrades CytomX Therapeutics to Buy, Price Target at $8	05-06	MT
JPMorgan Upgrades CytomX Therapeutics to Neutral From Underweight	04-22	MT
CytomX Therapeutics, Inc. Announces First Patient Dosed with CX-2051, A Conditionally Activated EpCAM-Directed ADC, in A Phase 1 Study in Patients with Advanced Solid Tumors	04-08	CI
CytomX Therapeutics, Inc. Appoints Dr. Zhen Su to Board of Directors	03-21	CI
CytomX Therapeutics, Inc. Announces Milestone Achievement in Prospective T-Cell Engaging Bispecific Collaboration with Astellas	03-18	CI
Transcript : CytomX Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 11:45 AM	03-14
BMO Capital Adjusts CytomX Therapeutics Price Target to $3.25 From $3.30, Maintains Market Perform Rating	03-12	MT
North American Morning Briefing : Inflation Data Back in the Spotlight	03-12	DJ
Stocks to Watch : Oracle, Mission Produce, CytomX Therapeutics	03-11	DJ
CytomX Therapeutics Shares Fall 19% After Bristol Myers Squibb Decides Not to Continue Developing Candidate	03-11	DJ
Transcript : CytomX Therapeutics, Inc., Q4 2023 Earnings Call, Mar 11, 2024	03-11
Earnings Flash (CTMX) CYTOMX THERAPEUTICS Reports Q4 Revenue $26.6M, vs. Street Est of $21.2M	03-11	MT
CytomX Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-11	CI
CytomX Therapeutics, Inc. Announces FDA Clearance of IND Applications for CX-2051, a Probody Antibody Drug Conjugate Targeting EpCAM and CX-801, a Conditionally Activated Interferon Alpha-2b	01-24	CI
Transcript : CytomX Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 05:15 PM	01-10
Wedbush Lifts CytomX Therapeutics' PT to $3 From $2, Says Focused Pipeline Moving Forward; Keeps Neutral Rating	11-09	MT

Chart CytomX Therapeutics, Inc.

Duration

Period

More charts

CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company focused on developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. It is advancing potential first-in-class and best-in-class antibody-based therapeutics created using its PROBODY therapeutic technology platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities including antibody-drug conjugates (ADCs), T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-904, CX-2051 and CX-801. CX-904 is a conditionally activated T-cell-engaging antibody targeting the epidermal growth factor receptor on tumor cells and the CD3 receptor on T cells and partnered with Amgen in a global co-development alliance. CX-2051 is a conditionally activated ADC directed toward epithelial cell adhesion molecule (EpCAM) with potential applicability across multiple EpCAM-expressing epithelial cancers.

Sector

Biotechnology & Medical Research

Calendar

2024-08-06 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for CytomX Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.22 USD

Average target price

5.318 USD

Spread / Average Target

+335.90%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
CYTOMX THERAPEUTICS, INC.	-21.29%	95.06M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B

Bio Therapeutic Drugs